DLX6-AS1

ncRNA information

ncRNA name

DLX6-AS1

Specific or universal ncRNAs

Specific ncRNAs

Class

Long noncoding RNA

Biomarker

None

Biomarker application

Upstream regulatory factors

Not available

Downstream target

Mir-199b-5p/Paxillin

Cancer information

Cancer name

Triple-Negative Breast Cancer

Cancer site

qRT-PCR,Western blot,Luciferase assay

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Up

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis

Tissue resource

tumor tissues and adjacent normal tissues

human breast fibroblast cell lines CCD-1095Sk

human triple-negative breast cancer cell lines HCC1599

human triple-negative breast cancer cell lines MDA-MB-231

human triple-negative breast cancer cell lines HCC1806

human triple-negative breast cancer cell lines HS578T

Experiment

None


Institute

First Affiliated Hospital of Zhengzhou University

American Type Culture Collection

Country

China

United States

Continent

Asia

North Amercian